On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...

Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...

PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing correction in a Phase I trial.

Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...

US pharma giant Eli Lilly has axed its Phase IIb trial of tirzepatide and bimagrumab, which was exploring the efficacy and safety of the combination in patients with obesity who have comborbid type 2 ...

Anebulo prioritised developing selonabant IV formulation as a potential treatment for paediatric patients with acute cannabis toxicity. Credit: murat photographer / Shutterstock.com. Anebulo ...

The FICS platform can accelerate study conduct by 50% while ensuring audit-ready data quality. Credit: Gorodenkoff / Shutterstock.com. Pi Health has announced a partnership to deliver completely ...

Tom Gottschalk, Prasun Mishra, and Luiz Barberini expounded the foundational role AI and blockchain will play in the future of clinical trials. Credit: Athanasios Psimadis/ Arena International Events ...

atai Life Sciences and Beckley Psytech’s psychedelic has demonstrated significant efficacy in a Phase IIa trial, meaning the companies will now progress BPL-003 (intranasal mebufotenin benzoate) to ...

MBX Biosciences announced the Phase II data from the Avail trial. Image credit: Poetra.RH / Shutterstock.com MBX Biosciences is advancing its hypoparathyroidism drug after 63% of patients achieved the ...